

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boyle, et al.

Serial No.: 09/613,591

Group Art Unit No.:

Filed: July 10, 2000

Examiner:

For: COMBINATION THERAPY FOR CONDITIONS
LEADING TO BONE LOSS

Docket No.: A-378CIP5

INFORMATION DISCLOSURE STATEMENTAssistant Commissioner for Patents
Washington, D.C. 20231

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form. The relevance of each listed reference is discussed in the following paragraphs.

In accordance with 37 CFR 1.98(d), copies of the patents, publications or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior applications. Applicants refer to the information disclosed in prior application Serial No. 09/457,647, filed December 9, 1999. The present application is a continuation-in-part of application Serial No. 09/457,647, filed December 9, 1999, which is a continuation-in-part of application Serial No. 09/350,670, filed July 9, 1999, which is a continuation-in-part of 08/706,945, filed September 3, 1996, which is a continuation-in-part of 08/577,788, filed December 22, 1995, which applications were relied upon for an earlier filing date under 35 U.S.C. 120. The information disclosed in the prior applications were submitted in accordance with 37 C.F.R. 1.97.

Applicants' position regarding this information and its relevancy remains unchanged.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231, on the date appearing below.

November 6, 2000
DateChristina A. Gutierrez
Signature

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,



Timothy J. Gaul
Attorney for Applicants
Registration No.: 33,111
Phone: (805) 447-2688
Date:

Please send all future correspondence to:

US Patent Operations/ TJG
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799